Glen Clova Scientific Announces Clinical Advisory Board for its Immuno-Dermatology Pipeline

Dundee, UK, 09 October 2025 – Glen Clova Scientific (GCS), a biotechnology company developing breakthrough therapeutics for treatment of immuno-dermatological conditions, is pleased to announce the establishment of its Clinical Advisory Board (CAB).

The Clinical Advisory Board will be chaired by Professor Alan Irvine, Professor of Dermatology at Trinity College Dublin and a Consultant Dermatologist in Children’s Health Ireland (CHI), St James’s Hospital, Dublin.

Joining Professor Irvine on the CAB are:

• Professor Gil Yosipovitch – Professor of Dermatology at the Miller School of Medicine, University of Miami, and Director of the Miami Itch Center
• Professor Sonja Ständer – Professor of Dermatology and Neurodermatology at the University of Münster and Head of the Interdisciplinary Center for Chronic Pruritus (KCP) at the University Hospital Münster
• Dr Huub Gelderblom – Physician-Scientist and Director of Strategic Partnerships, HIV Vaccine Trials Network (HVTN) at the Fred Hutchinson Cancer Center, Seattle.

Together, these key opinion leaders will support GCS’s leadership and R&D team to guide development strategy for its next generation of active biologics, including the Company’s lead asset GCS001.

Dr John Foerster, Chief Scientific Officer and Co-Founder of Glen Clova Scientific, commented: “We will benefit greatly from the knowledge and expertise of Prof Alan Irvine, Prof Gil Yosipovitch, Prof Sonja Ständer and Dr Huub Gelderblom through Glen Clova’s Clinical Advisory Board. Their input will be invaluable to us as we progress GCS’ product programmes towards clinical development.”

GCS001 is being developed as a first-in-class therapeutic vaccine for chronic pruritus, a debilitating condition that significantly impacts the quality of life for millions of patients worldwide, particularly across the elderly and those in long-term care. Current treatment options such as monoclonal antibodies are costly, limiting patient access. By contrast, GCS’s novel approach harnesses its proprietary virus-like particle (VLP) platform to deliver longer lasting therapeutic benefit with potentially just two injections per year in a format that is scalable and could be more widely accessible than monoclonal antibodies.

Beyond pruritus, GCS is advancing additional programmes in immune-dermatology conditions and exploring broader applications of its VLP technology in veterinary medicine and vaccine development.